Role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer

Current Oncology

Volumn 10, Issue 3, 2003, Pages 146-160

  Hodson, D Ian ^a   Browman, G ^b   Thephamongkhol, K ^b   Oliver, T ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; FEVER; HEAD CANCER; HEALTH CARE COST; HUMAN; HYPOTENSION; INFECTION; INTRAVENOUS CATHETER; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NECK CANCER; PRACTICE GUIDELINE; QUALITY OF LIFE; RADIATION INJURY; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SQUAMOUS CELL CARCINOMA; VEIN INJURY; VOMITING; XEROSTOMIA;

EID: 1542377417     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Hodson DI, Haines T, Berry M, Johnston M, and the Head and Neck Cancer Disease Site Group. Symptomatic treatment of radiation induced xerostomia in head and neck cancer patients. Curr Oncol 1999;6:155-60.
2. Warde P, O'Sullivan B, Aslanidis J, et al. A phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;54:9-13.
3. Scarantino C, Leveque FG, Scott C, et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09 [abstract 152]. Int J Radiat Oncol Biol Phys 2001;51(suppl 1):85-6.
4. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
5. Brizel DM, Wasserman TH, Strnad V, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-45.
6. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000;18:2226-33.
7. Buntzel J, Monnier A, Ammon J, et al. Phase III randomized double blind placebo controlled trial of carboplatin and radiation therapy ± amifostine in patients with head and neck cancer [abstract 151]. Int J Radiat Oncol Biol Phys 2001;51(suppl 1):85.
8. Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of postoperative radiochemotherapy ± amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 2003;179:385-9.
9. Antonadou D, Pepelassi E, Synodinou M, Puclisi M, Throuvalas N. The prophylactic use of amifostine in the prevention of chemoradiation induced mucositis and xerostomia in head and neck cancer [abstract 1031]. Int J Radiat Oncol Biol Phys 1998;42(suppl 1):224.
10. Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998;9:505-9.
11. Peters K, Mucke R, Hamann D, Ziegler PG, Fietkau R. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine? Strahlenther Onkol 1999;175(suppl 4):23-6.
12. Bardet E, Martin L, Calais G, etal. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 2002;29(suppl 19):57-60.
13. Wasserman T, Mackowiak JI, Brizel DM, et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 2000;48:1035-9.
14. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-903.
15. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-55.
16. Liu T, Liu Y, He S, Zhang Z, Kligerman MM. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992;69:2820-5.
17. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol 1998;16:3542-9.
18. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
19. Bourhis J, De Crevoisier R, Abdulkarim B, et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000;46:1105-8.
20. Rudat V, Meyer J, Momm F, et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiat Oncol Biol Phys 2000;48:1339-43.
21. European Organization for Research and Treatment of Cancer. EORTC protocol 24981. Phase II randomized study of paclitaxel and carboplatin followed by cisplatin and radiotherapy with or without amifostine in patients with locally advanced undifferentiated nasopharyngeal canacer. 2001. [Available at www.cancer.gov/clinicaltrials/view_clinicaltrials.aspx?version= healthprofessional&cdrid=68947&protocolsearchid=673757; accessed December 15, 2003]
22. Vincent M, Bramwell V, Moran L, Anderson D, and the Systemic Treatment Disease Site Group. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Curr Oncol 2000;7:149-61.
23. Wagner W, Radmard A, Schonekaes KG. A new administration schedule for amifostine as a radioprotector in cancer therapy. Anticancer Res 1999;19:2281-3.
24. Anné P, Curran W, Machtay M, et al. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer (WR-B060) [abstract 150]. Int J Radiat Oncol Biol Phys 2001;51(suppl 1):84.
25. Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 2001;19:107-13.
26. Bonomi AE, Palmer CS, Ajax M, Peeples P, Jackson SE. Cost of managing mucositis and xerostomia in head and neck cancer patients undergoing radio-chemotherapy (CRT) or radiation (RT) [abstract PCD 12]. Value Health 1999;2:197.